Biotech News
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated by the EMA and European Commercialization Rights to D-PLEX₁₀₀ Regained “PolyPid 2030” Growth Strategy Unveiled,
